Clinical Determinants of the Severity of COVID-19: A Systematic Review and Meta-analysis
Overview
Affiliations
Objective: We aimed to systematically identify the possible risk factors responsible for severe cases.
Methods: We searched PubMed, Embase, Web of science and Cochrane Library for epidemiological studies of confirmed COVID-19, which include information about clinical characteristics and severity of patients' disease. We analyzed the potential associations between clinical characteristics and severe cases.
Results: We identified a total of 41 eligible studies including 21060 patients with COVID-19. Severe cases were potentially associated with advanced age (Standard Mean Difference (SMD) = 1.73, 95% CI: 1.34-2.12), male gender (Odds Ratio (OR) = 1.51, 95% CI:1.33-1.71), obesity (OR = 1.89, 95% CI: 1.44-2.46), history of smoking (OR = 1.40, 95% CI:1.06-1.85), hypertension (OR = 2.42, 95% CI: 2.03-2.88), diabetes (OR = 2.40, 95% CI: 1.98-2.91), coronary heart disease (OR: 2.87, 95% CI: 2.22-3.71), chronic kidney disease (CKD) (OR = 2.97, 95% CI: 1.63-5.41), cerebrovascular disease (OR = 2.47, 95% CI: 1.54-3.97), chronic obstructive pulmonary disease (COPD) (OR = 2.88, 95% CI: 1.89-4.38), malignancy (OR = 2.60, 95% CI: 2.00-3.40), and chronic liver disease (OR = 1.51, 95% CI: 1.06-2.17). Acute respiratory distress syndrome (ARDS) (OR = 39.59, 95% CI: 19.99-78.41), shock (OR = 21.50, 95% CI: 10.49-44.06) and acute kidney injury (AKI) (OR = 8.84, 95% CI: 4.34-18.00) were most likely to prevent recovery. In summary, patients with severe conditions had a higher rate of comorbidities and complications than patients with non-severe conditions.
Conclusion: Patients who were male, with advanced age, obesity, a history of smoking, hypertension, diabetes, malignancy, coronary heart disease, hypertension, chronic liver disease, COPD, or CKD are more likely to develop severe COVID-19 symptoms. ARDS, shock and AKI were thought to be the main hinderances to recovery.
Cullen M, Zhou X, Kelly S, Liang C, Li L, Shen R Curr Ther Res Clin Exp. 2024; 101:100757.
PMID: 39649410 PMC: 11625212. DOI: 10.1016/j.curtheres.2024.100757.
Medina M, Fuentes-Villalobos F, Quevedo C, Aguilera F, Riquelme R, Rioseco M Elife. 2024; 13.
PMID: 39470726 PMC: 11521369. DOI: 10.7554/eLife.94242.
Paranilam J, Arcioni F, Franco A, Lai K, Brown J, Kimball-Carroll S Infect Dis Ther. 2024; 13(11):2227-2253.
PMID: 39382830 PMC: 11499477. DOI: 10.1007/s40121-024-01051-9.
Mei A, Senthinathan A, Hussain S, Tadrous M, Noonan V, Jaglal S Healthcare (Basel). 2024; 12(17).
PMID: 39273823 PMC: 11395670. DOI: 10.3390/healthcare12171799.
Tuhkuri Matvejeff A, Laitinen A, Korhonen M, Oksanen L, Geneid A, Sanmark E PLoS One. 2024; 19(9):e0302250.
PMID: 39264883 PMC: 11392323. DOI: 10.1371/journal.pone.0302250.